Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex and aspirin drug-drug interaction study in healthy male volunteers
NL-OMON34161Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex and aspirin, sponsored by Merck & Co. Primary endpoint: Collagen-induced whole blood aggregometry. Started Feb 2011; status: active, not recruiting.
02
Drugs
Sugammadexaspirin
Beyond the preview
Go deeper on NL-OMON34161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34161.